We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Data Integrity Issues in Clinical Trials Lead to Approval Delays
Data Integrity Issues in Clinical Trials Lead to Approval Delays
The data integrity issues most likely to lead to a delay in FDA marketing approval for new drugs include poor quality control for data entry, systemic errors at clinical study sites and database changes made after an initial database lock and study unblinding.